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http://www.biomedcentral.com/1471-2377/13/73RESEARCH ARTICLE Open AccessNo sex-specific difference in disease trajectory in
multiple sclerosis patients before and after age 50
Riley Bove1,2, Alexander Musallam1, Brian C Healy1,2,3, Maria Houtchens1,2, Bonnie I Glanz1, Samia Khoury1,2,
Charles R Guttmann1,2, Philip L De Jager1,2,4 and Tanuja Chitnis1,2*Abstract
Background: The disease course in multiple sclerosis (MS) is influenced by many factors, including age, sex, and
sex hormones. Little is known about sex-specific changes in disease course around age 50, which may represent a
key biological transition period for reproductive aging.
Methods: Male and female subjects with no prior chemotherapy exposure were selected from a prospective MS
cohort to form groups representing the years before (38–46 years, N=351) and after (54–62 years, N=200)age 50.
Primary analysis assessed for interaction between effects of sex and age on clinical (Expanded Disability Status
Scale, EDSS; relapse rate) and radiologic (T2 lesion volume, T2LV; brain parenchymal fraction, BPF) outcomes.
Secondarily, we explored patient-reported outcomes (PROs).
Results: As expected, there were age- and sex- related changes with male and older cohorts showing worse
disease severity (EDSS), brain atrophy (BPF), and more progressive course.
There was no interaction between age and sex on cross-sectional adjusted clinical (EDSS, relapse rate) or radiologic
(BPF, T2LV) measures, or on 2-year trajectories of decline.
There was a significant interaction between age and sex for a physical functioning PRO (SF-36): the older female
cohort reported lower physical functioning than men (p=0.002). There were no differences in depression (Center for
Epidemiological Study – Depression, CES-D) or fatigue (Modified Fatigue Impact Scale, MFIS) scores.
Conclusions: There was no interaction between age and sex suggestive of an effect of reproductive aging on
clinical or radiologic progression. Prospective analyses across the menopausal transition are needed.
Keywords: Demyelinating disease, Multiple sclerosis, Natural history studies, MRI, Disease progression, Menopause,
GenderBackground
Multiple sclerosis (MS) affects almost three times more
women than men. The incidence and disease course of
MS are modulated by a complex interplay among genetic
susceptibility, sex hormones, and the environment [1-3].
Both sex and age influence disease course, with both
advanced age and male sex associated with worsening
disability and more rapid progression of disease [4-8].
Interestingly, we found that women whose onset of MS
symptoms occurred after age 50 are more likely to have a
progressive course than women with an earlier symptom* Correspondence: tchitnis@rics.bwh.harvard.edu
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reproduction in any medium, provided the oronset, and the female: male ratio for individuals in
this group is lower than in individuals with onset
between ages 18-49 [9].This suggests that the endocrine
changes associated with menopause may reduce sexual
dimorphism in disease course in later years.
In this study, we use prospectively collected data to
examine disease course in men and women with MS in
cohorts that represent the years before and after age 50.
We examine the interaction between age and sex to test
the hypothesis that women experience acceleration in
their trajectory of decline after age 50, relative to similarly
aged men [10].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Subjects
The Partners Multiple Sclerosis Center is a regional MS
referral center in the Northeastern United States. To date,
over 2000 of our patients are enrolled in our detailed
longitudinal cohort study (Comprehensive Longitudinal
Investigation of Multiple Sclerosis at the Brigham and
Women’s Hospital, CLIMB), with follow-up for an
average of 2.6 (SD 2.8) years. All CLIMB patients
have a diagnosis of MS as defined by the 2005
McDonald criteria, or a clinically isolated syndrome
(CIS) with an MRI suggestive of MS. Demographic
characteristics (race and ethnicity by NIH criteria)
and complete MS history are recorded upon enroll-
ment. Neurological examinations are obtained every 6
months, and brain MRIs annually. We excluded
subjects with prior exposure to cyclophosphamide
and mitoxantrone, to minimize potential confounding
effects of iatrogenic menopause.
For this study, we divided subjects into twoage
cohorts, aged before and after 50: Cohort 1 (C1): ages
38–46 (n=351), and Cohort 2 (C2): ages 54–62 (n=200).
The menopausal transition involves a series of physiological
changes associated with reproductive senescence in women,
divided into a series of stages [11]. Operationally,
menopause is defined as the final menstrual period,
after which no further menses occur during a 12-month
interval.The mean age at menopause in Western societies
is 49-52 [12,13], and preliminary analysis of a reproductive
history questionnaire in our clinic cohort suggests a
median age of 50.7 years (unpublished data). Thus, while
recognizing variability in individual age at menopause,
cohorts C1 and C2 were designed to capture women
before and after age 50 (ages 38–46 and 54-62), to
minimize the effect of marked hormonal fluctuations
at the time of menopause itself on disease character-
istics.A subset of these subjects had at least two
years of follow-up and therefore contributed to our
analysis of change in the prior two years (N=169
and 97). We included men in these age groups in
addition to women in order to provide a control
group for sexcomparisons. Institutional Review Board
approval was granted by the Partners Human
Research Committee. Informed consent for use of
clinical data and MRI information was obtained from
all study subjects.
Clinical outcomes
The expanded disability status scale (EDSS [14]) score
and the disease category (CIS, relapsing remitting,
secondary progressive, primary progressive [15]) were
recorded every 6 months by the treating physician. In
addition, the occurrence of clinical relapses in the
interval between visits was recorded.MRI protocol/segmentation
Subjects were scanned with a T2-weighted axial dual
echo protocol covering the whole brain (TR=3000 ms,
TE=30/80 ms, 192 phase encoding steps, 256×256×54
voxels with 0.93 × 0.93×3 mm3 nominal voxel size and
no interslice gaps). All baseline and follow-up scans were
performed on the same 1.5 Tesla machine (GE Signa,
General Electrics, Milwaukee, WI).T2LV was determined
by semi-automated outlining using local thresholding and
manual editing (3D Slicer 3.4, http://www.slicer.org/).
Automated template driven segmentation identified
normal appearing white matter, grey matter and CSF.
Head size normalized BPF was calculated as follows: (grey
matter + white matter + T2LV)/intracranial volume [16].
Patient reported outcomes (PROs)
In a subgroup, the following scales were completed
annually: Center for Epidemiological Studies Depression
Scale (CES-D [17]), Modified Fatigue Impact Scale (MFIS
[18]) for fatigue, and general quality of life (SF-36 [19]).
The MFIS and SF-36 were scored using the algorithm
from the Multiple Sclerosis Quality of Life Inventory [20].
Statistical methods
Our primary goal was to assess the interaction between
age and sex on each of our clinical and MRI measures.
Secondarily, we assessed PROs.
The patient characteristics at the last visit were used
for this first set of analyses. To determine if the impact
of age was different in the two sexes, the interaction
between age group and sex was assessed using linear
regression for the MRI and PRO outcomes, negative
binomial regression for the number of attacks in the pre-
vious 2 years, and proportional odds logistic regression
for EDSS. The T2 lesion volume was log-transformed for
this analysis. An analysis using the cube root of the
lesion volume produced the same results as the analysis
using the log-transformed lesion volume, and thus only
the results from the latter are presented. The interaction
analysis was also completed adjusting for disease duration
and disease category. There were two models for disease
category; the first included an indicator for current relaps-
ing course (CIS, RRMS) versus current progressive course
(PPMS, SPMS), while the second included an indicator for
relapsing onset (CIS, RRMS, SPMS) versus progressive
onset (PPMS). Since the results were largely unchanged
between these two analyses, only the first are reported.
This analysis compared the C1 and C2 cohorts. In addition
to the interaction analysis, we investigated the separate
effect of age and sex by stratifying on both sex and age. For
our investigation of the effect of age, the two cohorts were
compared in the males and females separately using a
t-test for PROs, age, age at onset, and disease duration; a
Wilcoxon test for the EDSS and relapse rate; and Fisher’s
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type. To investigate the impact of sex with each age
cohort, the same approaches were used.
In addition to the characteristics at last visit, the rate of
change in the EDSS, MRI and PRO outcomes were investi-
gated using a random intercepts model. As in the cross-
sectional analysis, the primary analysis investigated the
interaction between age and sex on the rate of change. The
secondary analyses compared the rates of change in the age
cohorts for each sex separately, and the rate in each sex
was compared in each cohort separately. All analyses were
completed in the statistical package R (www.r-project.org)
and SAS Software (Version 9.2).
Results
Patient characteristics
We found that increasing age affected the distribution of
several clinical parameters among CLIMB patients from
the Partners MS Center (Boston, MA) who were from
cohorts aged under 50 (C1: 38–46 years) and over 50
(C2: 54–62 years) (Table 1). Most notably, in both men
and women, individuals in C2 had an older age at onset
(p<0.0001). Nonetheless, the mean disease duration from
symptom onset remained longer in the older C2 subjects
(women p<0.0001 and men p=0.02). While the propor-
tion of RRMS/CIS subjects declined in the older cohort
of subject, this parameter was only significantly different
in women (p<0.0001).Table 1 Sociodemographic characteristics presented by sex and
Female
Cohort (years) C1 C2 C1 vs. C2
38-46 54-62 p
N 258 153
Age (yrs)
mean 42.36 57.97
std. dev 2.66 2.47
Race (% white)+ 95.2 95.4 1
Ethnicity (% hispanic)* 3.6 0.7 0.098
Current course type (%) <0.0001
Relapsing (RRMS, CIS) 96.5 77
SPMS 2.4 15.7
PPMS 1.2 6.5
Disease duration (yrs) <0.0001
Mean 9.93 16.76
std. dev. 6.02 9.47
Age at disease onset (yrs) 32.42 (6.27) 41.21 (9.65) <0.0001
RRMS, CIS Mean (SD) 32.39 (6.33) 41.32 (9.76) <0.0001
SPMS Mean (SD) 31.83 (4.17) 37.71 (8.65) 0.120
PPMS Mean (SD) 36.00 (4.36) 46.20 (8.18) 0.067
+8 missing and did not contribute to the analyses *9 missing and did not contributWhen we compared men and women within each age
cohort, significantly more women than men had a
relapsing course (p=0.001) in C1. In C2, women had a
modest younger age at symptom onset (p=0.05) and
increased disease duration (p=0.01).
Objective clinical and radiologic outcomes
Cross-sectional analysis
To address the question of whether disease course
changes after age 50, we assessed whether there was
evidence for statistical interaction between age and
sex in their influence on clinical (EDSS, relapse rate)
and radiologic (T2 lesion volume, BPF) outcomes
when comparing the C1 and C2 age cohorts. No evidence
for interaction was observed in the unadjusted analysis
and in analyses adjusted for disease duration and disease
category (Table 2). Thus, the difference between
women and men was similar in both age cohorts on
cross-sectional analysis.
Comparing C1 and C2, we saw the expected increase
in EDSS and decline in relapse rate and BPF with
increasing age, for both women (p<0.0001) and men
(p=0.02 for EDSS, p=0.03 for relapse rate and p<0.0001
for BPF) (Table 2). When we compared women and men
in each age cohort, C1 women had a lower EDSS than
men (p=0.03).Additionally, BPF was consistently lower
in men relative to women in both age cohorts (p<0.001)age cohort (p-values for comparison analyses are provided)
Male Male vs. Female
C1 C2 C1 vs. C2 C1 C2
38-46 54-62 p p p
93 47
0.32 0.29
42.04 57.51
2.56 2.66
95.7 93.6 0.687 1 0.703
1.1 0 1 0.301 1
0.0031 0.0011 0.0097
86 72.3
10.8 6.4
3.2 21.3 1.2 6.5
0.01 0.71 0.01
9.68 13.15
5.66 8.45
32.37 (5.99) 44.36 (9.24) <0.0001 0.94 0.05
32.94 (5.72) 44.35 (8.75) <.00001 0.49 0.105
27.90 (5.78) 38.67(10.41) 0.036 0.169 0.860
32.00 (9.54) 46.10 (10.87) 0.069 0.545 0.982
e to the analysis.
Table 2 Cross-sectional disease characteristics compared by age cohort (ages 38–46 vs. 54–62 years) and by sex
Female Male Female vs.Male Adjusted
interaction analysis
age cohort*sexCohort (years) C1 C2 p
C1 C2
p
C1 C2
38-46 54-62 38-46 54-62 p p
Clinical characteristics
(mean +/- SD)
EDSS* 1.42 (1.33) 2.39 (1.99) <0.0001 1.98 (1.88) 2.82 (2.31) 0.02 0.03 0.32 0.6
Relapse rate in prior two years % 0.34 (0.64) 0.05 (0.27) <0.0001 0.41 (0.83) 0.05 (0.22) 0.03 0.84 0.84 0.84
MRI characteristics
(mean +/- SD) +
BPF 0.88 (0.04) 0.85 (0.04) <0.0001 0.85 (0.04) 0.81 (0.04) <0.0001 0.0002 0.0004 0.34
T2 Lesion volume 3.91 (3.06) 5.29 (5.76) 0.11 4.42 (3.84) 6.11 (6.31) 0.41 0.36 0.63 0.98
Patient-reported outcomes
(mean +/- SD) ^
CES-D 29.5 (8.28) 28.18 (8.24) 0.26 30.94 (8.22) 29.86 (8.53) 0.63 0.3 0.43 0.93
MFIS 24.64 (16.27) 28.52 (16.9) 0.1 27.33 (20.23) 28.24 (19.52) 0.86 0.42 0.95 0.5
SF-36 PCS 49.08 (8.99) 45.34 (11.08) 0.01 48.85 (9.14) 46.44 (10.77) 0.37 0.88 0.68 0.55
SF-36 MCS 49.05 (10.02) 50.03 (9.26) 0.48 47.51 (9.12) 48.11 (8.7) 0.8 0.33 0.37 1
Legend: EDSS, expanded disability status scale, BPF, brain parenchymal fraction, CES-D, Center for Epidemiological Study, MFIS, Modified Fatigue Impact Scale *:
N=551. The group comparisons were completed with a Wilcoxon test, and the interaction analysis was completed with a proportional odds model %: N=285.
The group comparisons were completed with a Wilcoxon test, and the interaction analysis was completed with a negative binomial regression model +: N=308.
The BPF and log-transformed T2 lesion volume were compared using a t-test, and the interaction analysis was completed with linear regression ^: N=287.
All comparisons were made using a t-test, and the interaction analysis was completed with linear regression.
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Given the availability of longitudinal data, we also examined
the accumulation of MS-related disability in subjects aged
before and after 50 years. Specifically, we compared the
slope of change over a 2-year period in clinical and
radiologic parameters between cohorts C1 and C2.
The interaction analysis demonstrated no significant
interaction between age and sex in any outcome (Table 3).
Additionally, the slope of decline in these clinical and
MRI parameters was not significantly different between
the C1 and C2 age cohorts, suggesting that, within
the sampled time frame, there does not appear to be
a significant acceleration of decline as MS subjects go
from earlier to later middle age. Men and women also
did not differ in either cohort for 2-year changes in
clinical and radiologic parameters.Patient reported outcomes (PRO’s)
To explore the possibility that other features of MS may
be influenced by reproductive aging, we assessed cross-
sectional and longitudinal data collected using three
different instruments: CES-D (depression), MFIS (fatigue)
and SF-36 (quality of life, QOL). In the cross-sectional
summary measures for these instruments, our analysis
revealed a significantly lower physical symptom summary
score (PCS) in the C2 female cohort (p=0.01) relative to
C1 women, but not in the male cohorts (p=0.88) (Table 2).In a secondary analysis of the SF-36 sub-scores, we noted
the presence of a substantially lower SF-36 “physical
functioning” score for women in C2 relative to C1
(p<0.0001), but not for men (p=0.46) (Additional file 1:
Table S1). However, there was no interaction between age
and sex and any PRO outcome, in either the unadjusted
or the adjusted analyses.
In longitudinal analysis, the secondary analysis of the
SF-36 sub scores revealed a significant interaction
between age and sex in terms of the change in the over-
time in the physical functioning sub score (p=0.002). There
were no other significant differences between female age
cohorts after a Bonferroni correction for multiple com-
parisons (Additional file 1: Table S1). There were no other
significant interaction terms in longitudinal analyses of our
PRO data. Thus, while there was no acceleration noted in
the trajectories of decline of subjects after the age of
50 using clinical and MRI measures, female subjects
may report an altered perception of their physical
function at this stage of their life course.Discussion and conclusion
In this study, we investigated whether female subjects
may experience a more rapid decline after age 50, out of
proportion with the age-related decline that male subjects
also experience at this stage of their life. Estrogen
may mediate neuroinflammatory signals and protect
Table 3 Longitudinal change in clinical, radiologic and patient-reported outcomes compared by age cohort
(ages 38–46 vs. 54–62 years) and by sex (slopes of change over preceding 2 years are compared)
Female Male Female vs. Male Adjusted
interaction analysis
Cohort (years)
C1 C2
p
C1 C2
p
C1 C2
38-46 54-62 38-46 54-62 p p
Age Cohort*Sex
N 128 78 41 19
Clinical characteristics
EDSS 0.139 0.122 0.83 0.152 -0.066 0.11 0.876 0.201 0.22
MRI characteristics
BPF -0.001 -0.001 0.7 -0.002 -0.004 0.3 0.336 0.193 0.48
T2 lesion volume -0.002 0.025 0.34 0.019 -0.038 0.18 0.54 0.121 0.14
Patient-reported outcomes
CES-D 0.22 0.705 0.36 -0.146 0.056 0.82 0.526 0.456 0.74
MFIS 0.17 1.045 0.27 -0.475 0.806 0.37 0.549 0.846 0.86
SF-36 PCS -0.061 -0.349 0.5 0.196 1.111 0.26 0.628 0.052 0.16
SF-36 MCS -0.357 -1.304 0.17 0.259 -0.858 0.33 0.419 0.632 0.99
Legend: EDSS, expanded disability status scale, BPF, brain parenchymal fraction, CES-D, Center for Epidemiological Study, MFIS, Modified Fatigue Impact Scale.
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prior studies, we found that both older age and male
sex influence the disease course of MS, with men
displaying a more progressive disease and more rapid
accumulation of disability as measured by clinical and
radiological outcomes [24,25]. However, we did not
find any interaction between age and sex that would
suggest a differential effect of menopause on these
outcomes.
In other inflammatory disorders, such as systemic
lupus erythematosis and rheumatoid arthritis, the onset
of menopause has been associated with altered disease
trajectory [26], presumably through estrogenic modula-
tion of immune cells. In epilepsy, another neurologic
disorder, the perimenopause is associated with exacerba-
tion of catamenial seizures, and the menopause, with a
decrease in seizure frequency. This may occur because
of changes in estrogenic modulation of synaptic regulation.
Peri-menopausal hormone replacement therapy (HRT) has
been associated with modulatory effects in these other
neurologic [27] and inflammatory diseases [26]. To our
knowledge there are no clinical data specifically assessing
an association between menopause and disease trajectory
in multiple sclerosis, and prior patient reports have been
variable, with a subset of women reporting worsening of
symptoms with menopause [28-30]. These small studies
also differed vastly in the reported effectiveness of HRT,
from limited utility to improvement in 75% patients.
Given our prior analyses revealing that MS with onset
after age 50 (late-onset MS) is more similar in women
and men than MS with onset before age 50, suggesting
an effect of menopause [9], the findings in this study were
somewhat surprising. While an expected age-relateddecline was observed, it was seen both in men and
women, suggesting that the change is not driven primarily
by changes in female sex hormones.
Patient-reported outcomes may capture different
aspects of subjects’ experience with MS than episodic
clinical and radiological assessments [31,32]. The
findings of worsening physical functioning in older
cohort of women suggest some sex-specific acceleration
of functional decline or at least in the perception of
this decline.
The major limitation of this study is that we were
presently unable to assess the specific age at menopause
in our female cohorts. Instead, we compared the trajector-
ies of men and women in defined age cohorts using an
approximation of the mean age of menopause in Western
society, and excluding individuals with exposure to chemo-
therapy, rather than following a cohort of women through
individual, well-characterized menopausal transition.
During the menopausal transition, endocrine shifts
may lead to a greater variability in inflammatory
activity, whereas thereafter, much lower estrogen
levels may make male and female profiles more simi-
lar and may be associated with more rapid clinical
deterioration. Thus, long-term longitudinal analyses of
women throughout their menopausal transition may be
more informative about specific endocrine-associated
disease patterns; however we were not able to address this
question with our current dataset. Second, given the
exploratory nature of this study, we included all available
patients in each age cohort, leading to limited older males
in particular. Given our sample sizes (258 females in C1,
153 females in C2, 93 males in C1 and 47 males in C2),
we had 80% power to detect interaction effects of at least
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this is a moderate effect size, our results demonstrate that
the difference between men and women in the two age
groups is not large, but to detect a mild to moderate
effect size larger sample sizes would be required.
Third, the two-year duration of follow up time may
be too short to identify clinically meaningful effects
and to identify divergent trajectories for men and
women. In addition, several other confounders such
as the proportion of post-menopausal women taking
HRT in this study, as well as the incidence of osteo-
porosis or other comorbidities common in MS and
potentially exacerbated at menopause [33] could not
currently be ascertained, which may have an effect on
measured outcomes. Further studies are underway to
assess this possibility.
In an era where unprecedented numbers of women
with MS are entering the menopausal transition with
relatively preserved clinical function, and for whom hor-
mone modulation therapies, if effective, may present a
different benefit: risk profile than in a healthy population
[34,35], further inquiries into this topic are crucial, in
order to confirm or contest these preliminary findings.
Our analyses suggest that large sample sizes maybe
required to complete the critical first step in this research
avenue, which is to better understand the potential effect
of menopause on disease activity.Additional file
Additional file 1: Table S1. Cross-sectional and longitudinal
patient-reported outcomes by sex for each age cohort (comparisons are
provided between age cohorts and between sexes).Abbreviations
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